ID   JOSK-K
AC   CVCL_8141
DR   BioSample; SAMN03151981
DR   cancercelllines; CVCL_8141
DR   Cosmic; 919121
DR   Wikidata; Q54899046
RX   PubMed=3486043;
RX   PubMed=9510473;
RX   PubMed=10508494;
RX   PubMed=12592342;
RX   PubMed=20143388;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v13_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a U-937 derivative (PubMed=10508494; PubMed=12592342; PubMed=20143388).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00136.
CC   Population: Caucasian.
CC   Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C8263; Adult acute monocytic leukemia
DI   ORDO; Orphanet_514; Acute monoblastic/monocytic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0007 ! U-937
SX   Male
AG   37Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 26
//
RX   PubMed=3486043;
RA   Ohta M., Furukawa Y., Ide C., Akiyama N., Utakoji T., Miura Y.,
RA   Saito M.;
RT   "Establishment and characterization of four human monocytoid leukemia
RT   cell lines (JOSK-I, -S, -M and -K) with capabilities of
RT   monocyte-macrophage lineage differentiation and constitutive production
RT   of interleukin 1.";
RL   Cancer Res. 46:3067-3074(1986).
//
RX   PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x; PMCID=PMC5921588;
RA   Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y.,
RA   Hirai H.;
RT   "Frameshift mutations of the hMSH6 gene in human leukemia cell
RT   lines.";
RL   Jpn. J. Cancer Res. 89:33-39(1998).
//
RX   PubMed=10508494; DOI=10.1002/(SICI)1097-0215(19991112)83:4<555::AID-IJC19>3.0.CO;2-2;
RA   MacLeod R.A.F., Dirks W.G., Matsuo Y., Kaufmann M., Milch H.,
RA   Drexler H.G.;
RT   "Widespread intraspecies cross-contamination of human tumor cell lines
RT   arising at source.";
RL   Int. J. Cancer 83:555-563(1999).
//
RX   PubMed=12592342; DOI=10.1038/sj.leu.2402799;
RA   Drexler H.G., Dirks W.G., Matsuo Y., MacLeod R.A.F.;
RT   "False leukemia-lymphoma cell lines: an update on over 500 cell
RT   lines.";
RL   Leukemia 17:416-426(2003).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//